By Natasha Pomelova, Founder of MedicalSpaLocator.com and melov.ai — 15 years in pharmaceutical commercialization at Takeda, Amgen, Astellas, and Horizon Therapeutics.
Why compounded semaglutide is no longer available
Compounded semaglutide was only ever legal under a shortage exception: when FDA determined Ozempic and Wegovy were in shortage, 503A and 503B pharmacies could compound semaglutide. In early 2025, FDA resolved the shortage designation, triggering hard deadlines — April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. Clinics receiving compounded semaglutide after those dates face real enforcement risk: FDA has issued warning letters and coordinated with FTC on deceptive semaglutide marketing.
The permanent exclusion proposal
In 2026, FDA proposed to permanently add semaglutide to the list of drugs that cannot be compounded under 503A or 503B regardless of future shortage status. The public comment period closes June 29, 2026. If finalized, no future shortage would re-open compounding access. Submit comments via regulations.gov if your program is affected. The practical implication for any clinic: begin transitioning your weight-loss program to branded GLP-1 prescribing and monitoring now, before the rule finalizes.
What med spas can legally offer in 2026
| Product | Type | Status | Cost to Patient |
|---|---|---|---|
| Wegovy (injectable) | Branded semaglutide | FDA approved | $1,300–$1,600/month list; ~$25–$150 with insurance/coupon |
| Oral Wegovy | Oral semaglutide | Approved; launched Dec 2025 | ~$1,200/month |
| Foundayo (orforglipron) | Non-peptide oral GLP-1 | FDA approved April 2026 | TBD — Q3 2026 launch pricing |
| Zepbound (tirzepatide) | GLP-1/GIP dual agonist | FDA approved | $1,000–$1,500/month list; self-pay vials ~$500 |
| Compounded semaglutide | Compounded | Not legally available — deadlines passed | N/A |
What changed in late 2025 and 2026
December 2025: Novo Nordisk launched oral semaglutide specifically approved for weight management, removing the argument that injectable was the only accessible form. April 2026: Eli Lilly's orforglipron (Foundayo) received FDA approval — the first oral small-molecule GLP-1 receptor agonist. Because orforglipron is not a peptide, it cannot be compounded under the same biological framework, further reducing FDA's tolerance for compounded GLP-1 alternatives across the class.
How to restructure your program now
Position your clinic as a prescribing and monitoring partner, not a compounder. That means physician or NP oversight for GLP-1 prescriptions, insurance navigation support (many commercial plans now cover Wegovy), body composition monitoring (InBody or DEXA), and integration with aesthetics — specifically skin-laxity treatment planning after significant weight loss. This model is more defensible, generates more long-term revenue per patient, and is what AI engines cite when answering "weight loss med spa near me." Related: The AI Visibility and Trust Index for Medical Spas. MedicalSpaLocator.com lists 18,000+ verified providers across 1,000+ U.S. cities. Run your free AI Visibility audit here.
Does your weight-loss program appear in AI answers?
We test ChatGPT, Perplexity, Gemini, Claude, and Google AI Overviews and score your clinic's visibility in one free report.
Get Free AI Audit →